A new treatment to prevent scarring in the cornea
Official title: A single dose anti-scarring therapeutic for the cornea
Funded at Dub Therapeutics INC. · NIH-10931420 · Data updated 2026-11-12
This study is testing a new eye drop treatment that aims to prevent and heal corneal scarring, which can hurt your vision, by using a special ingredient that targets a specific protein involved in the scarring process.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dub Therapeutics INC. NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project start | September 30, 2023 |
| Project end | July 1, 2025 |
| Funding year | 2024 |
| Award (this year) | $917,935 |
| NIH project number | 5R44EY035188-02 |
| Project ID | NIH-10931420 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a history of corneal injury, trauma, or infection who are at risk of developing scarring.
✕Less likely to help
Patients with existing irreversible corneal opacification or those who have already undergone corneal transplantation may not benefit from this research.
What this research studies
This research focuses on developing a therapeutic approach to prevent and treat corneal scarring, which can severely impair vision. The method involves using a self-delivery siRNA that targets a specific protein involved in the scarring process, allowing for effective delivery through eye drops. By reducing the activity of this protein, the treatment aims to prevent irreversible corneal opacification caused by injury or infection. This innovative approach seeks to provide a safer alternative to existing treatments that often have unpredictable results and significant side effects.
Why it matters
Potential benefit: If successful, this research could significantly improve vision preservation for millions of people at risk of corneal scarring.
How similar studies have gone: This approach is novel and has not been extensively tested in previous studies, making it a potentially groundbreaking advancement in corneal treatment.
Where this research is happening
-
Dub Therapeutics INC.
Syracuse, United States Active
Researchers
- Principal investigator: Williams, Tere M. — Dub Therapeutics INC.
- Study coordinator: Williams, Tere M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.